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Abstract 
Peritoneal metastasis from breast cancer is a serious and deadly condition only limited considered in the literature. 
Our aim was to study prevalence, risk factors, and prognosis of breast cancer peritoneal metastasis. We retrospectively 
analyzed 3096 women with a diagnosis of invasive breast cancer. We took into consideration presence and localiza-
tion of breast cancer distant metastasis as well as the possible risk factors and survival from the diagnosis of the breast 
cancer metastasis. The prevalence of breast cancer peritoneal metastases was 0.7 % (22/3096), representing the 7.6 % 
(22/289) of women affected by distant metastases. Moreover, independent risk factors for breast cancer peritoneal 
metastases resulted high grading, lobular invasive histology, and advanced T and N stage at diagnosis. Overall survival 
after metastasis diagnosis was shorter in women affected by peritoneal metastases or brain metastases in comparison 
to other metastatic women. Breast cancer peritoneal metastases were uncommon but not rare events with a poor 
prognosis after standard treatments.
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Background
Metastatic breast cancer represents an important chal-
lenge for breast specialists, and its incidence has not 
changed during the last decades, while we have assisted 
to a progressive reduction of locally advanced breast 
cancers and a consensual increase of early breast ones, 
thanks to the introduction of an organized mammo-
graphic screening in our region since 2005 (Driul et  al. 
2013; Cedolini et  al. 2014a). A first explanation may be 
that distant metastasis by haematogenous way do not 
depend on tumor size neither on lymph node involve-
ment, which is usually expression of metastatization by 
lymphatic way. Secondly, groups of patients who more 
frequently present distant metastasis from breast cancer 
do not usually represent a screening target, such as young 
pre-menopausal women.
Typical breast cancer metastatization sites are, in order 
of frequency, bones, liver, lungs and brain, but many 
other secondary localizations have been described in the 
literature, including the peritoneal cavity (Sheen-Chen 
et  al. 2008). In fact, although peritoneal carcinomatosis 
usually affects patients with solid intra-abdominal can-
cers, including those originated by the gastrointestinal 
tract and those originating by the female reproductive 
system (Pasqual et  al. 2014; Pasqual et  al. 2012), it may 
also derive from any other solid tumor of the human 
body.
Peritoneal carcinomatosis represents a lifethreating 
condition, with a very high mortality rate (Pasqual et al. 
2014; Pasqual et  al. 2012), which was historically sub-
jected to systemic chemotherapy, exclusively with a pal-
liative intent. Anyway, during the last two decades new 
loco-regional integrated treatments have been estab-
lished, in order to treat patients affected by peritoneal 
carcinomatosis, in some selected cases even with curative 
intent (Pasqual et  al. 2014; Pasqual et  al. 2012). In par-
ticular, surgical cytoreduction combinated to intraperi-
toneal chemotherapy, which was firstly introduced by 
Sugarbaker in 1995 showed very encouraging results in 
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improving both overall and disease-free survival of this 
group of patients (Sugarbaker 1995; Roviello et al. 2011).
Our study aims to determine the prevalence and risk 
factors for peritoneal carcinomatosis among breast can-
cer patients, and to compare their prognosis with that of 
other secondaries sites.
Methods
We collected retrospective data about 3096 women oper-
ated at their breast for invasive breast cancer. We focused 
on patients operated between 2001 and 2010, in order to 
have at least 4 years of follow up. We excluded women 
affected by intraductal neoplasia or benign breast dis-
eases. This retrospective chart review study was per-
formed according to the Declaration of Helsinki and 
approved by the Internal Review Board. In addition, 
this study regarding consent for processing data used 
in this retrospective analysis follows the dictates of the 
general authorisation to process personal data for sci-
entific research purposes by the Italian Data Protection 
Authority.
We took into consideration patients characteristics 
as follows: age and BMI (body mass index) at the time 
of diagnosis, familial history of breast cancer, eventual 
menopausal status and estro-proestinic drug assump-
tion. Among tumor characteristics we considered: his-
tological type, TNM classification and stage, eventual 
loco-regional extra-axillary lymph node involvement 
(internal mammary chain and subclavear), nuclear 
grading, Mib1/Ki-67 proliferation index, estrogen and 
progesteron receptors expression, Her2/neu status, 
and molecular subtypes. Moreover, we included other 
microscopical histological characteristics which are 
included in the more recent classification purposed by 
Veronesi and colleagues (Arnone et  al. 2010) as previ-
ously described (Cedolini et al. 2014a, b, c; Bertozzi et 
al. 2013; Bernardi et al. 2012a, b), including multifocal-
ity/multicentricity, extensive intraductal component, 
perivascular invasion, peritumoral inflammation, lymph 
node extra-capsular invasion, and presence of bunched 
lymph nodes. Finally, we took into consideration also 
the therapeutic management: type of intervention on 
the breast (conservative breast surgery or mastectomy) 
and the axilla (sentinel lymph node biopsy or complete 
lymph node axillary dissection), eventual neoadjuvant 
or adjuvant therapies (chemotherapy, hormonal therapy, 
biological drugs, radiation therapy).
Then, we identified the group of women affected by 
peritoneal metastasis from breast cancer, and compared 
them with non metastatic patients and those with dis-
tant metastasis other than peritoneum. In particular, 
peritoneal carcinomatosis was suspected in any women 
presenting with ascitis, or with a documented increase 
in CA125, or with unexplained anorexia and weigh loss 
of recent onset. Thereafter, in any case abdominal CT 
scan was performed, with or without additional FDG-
PET/CT, in order to confirm peritoneal involvement. By 
the presence of ascitis, peritoneal fluid cytology was also 
performed.
Data were analyzed using R (version 3.1.0: http://
www.R-project.org/), considering significant p  <  0.05. 
Distribution normality of each variable was assessed by 
Kolmogorov–Smirnov test. The following statistical test 
were used when appropriate: t test and Wilcoxon test for 
continuous variables, Chi-square test or Fisher exact test 
for categorical ones. Univariate and multivariate logis-
tic regression analysis was performed considering as 
dependent variables the presence of distant metastases or 
peritoneal metastases. Kaplan–Meier curves were drown 
to show overall survival, and the differences among the 
three groups were determined through the Log-rank test. 
Univariate and multivariate Cox proportional hazards 
regression models were performed considering the pos-
sible factors influencing survival.
Results
Among the 3096 considered women affected by inva-
sive breast cancer, 289 (9.33  %) presented a distant 
metastasis at the time of diagnosis or developed a 
metastasis at a median follow up of 83  months. Only 
1.8  % (57/3096) of cases were initially diagnosed as 
stage IV breast cancer, and thus a minority (19.7  %) 
of whole metastatic breast cancer population. Moreo-
ver, median survival after the diagnosis of metastasis 
resulted 28 months.
Distant metastases affected the following sites in 
order of frequency: bones 67.8 % (196/289), liver 47.8 % 
(138/289), lungs 42.6  % (123/289), distant lymph nodes 
27 % (78/289), brain 15.2 % (44/289), peritoneum (perito-
neal carcinomatosis) 7.6 % (22/289), and other sites 6.9 % 
(20/289). Only 29.8  % (86/289) of women had only one 
metastatic site involved, while in all other cases distant 
metastases affected more than one site. Moreover, the 
prevalence of peritoneal metastases was 0.7 % (22/3096).
Mean age at diagnosis of our population was 
60.15  years (±  13.03), mean BMI 25.86  kg/m2 (±4.93), 
and 74.9 % of women were in post-menopause. Surgical 
approach was conservative in the most cases. The major-
ity of breast cancers resulted to be non-special type (e.g. 
ductal invasive carcinoma) in the 76.3 % (2362/3096) of 
cases, small sized (T1) in the 72.4 % of cases, and without 
lymph node involvement (N0) in the 66.4 % of patients. 
Estrogen receptor was expressed even in the 84.1  % of 
cases. The more prevalent molecular subtype resulted 
luminal A in 31.2  % (966/3096) of cases, followed by 
luminal B in 23.8 % (738/3096) of patients, whereas only 
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a minority were diagnosed as basal-like or Her-enriched 
subtypes.
Comparing patients with peritoneal, non-peritoneal 
metastases, and without metastases, we can notice that 
women who develop peritoneal carcinomatosis (M1: per-
itoneum) were younger and have a lower BMI (Table 1). 
Moreover, they usually underwent more aggressive adju-
vant treatment, probably due to their unfavorable prog-
nosis at diagnosis, related to bad molecular subtypes, 
high grading and advanced TNM stage (Table 2). Finally, 
development of metastasis in the peritoneal cavity hap-
pened significantly later than those of any other site: at 
5 years follow up have already appeared 77.1 % (95 % C.I. 
70.5–82.2 %) of the non-peritoneal metastases while only 
60.0  % (95  % C.I. 25.7–78.5  %) of peritoneal metastases 
have appeared.
The multivariate logistic regression highlighted the 
following predisposing factors for breast cancer metas-
tasis: high grading, lobular invasive histotype (including 
ductal-lobular invasive carcinoma), molecular subtype 
other than luminal A, advanced TNM stage (including 
both big tumor size and high lymph node involvement) 
(Table  3a). Taking into consideration separately stage I, 
II and III at diagnosis, the multivariate logistic regression 
confirmed the previous predisposing factors for presence 
of distant metastases (Table 3b).
Furthermore, by multivariate logistic regression, the 
following factors resulted to be significantly predictive 
for the development of peritoneal metastasis: high grad-
ing, lobular invasive histotype (including ductal-lobular 
invasive carcinoma), and advanced TNM stage (including 
both big tumor size and high lymph node involvement) 
(Table  4a). Thereafter, considering separately stage I, II 
and III at diagnosis, the multivariate logistic regression 
confirmed the same predisposing factors for peritoneal 
metastatization, with the exception of grading and tumor 
size (Table 4b).
If we have a look at cumulative metastasis rates, we 
can see that after 10  years of follow up more than 5  % 
of breast cancer patients have a distant metastasis diag-
nosed. In addiction, among stage III patients more than 
25 % will develop a breast cancer metastasis during their 
Table 1 Characteristics of the population and differences among controls (M0) and women affected by peritoneal carci-
nomatosis (M1: peritoneum) or other site of metastases (M1: other than peritoneum)
Significant differences (p < 0.05) between: (1) M0 vs M1: other than peritoneum; (2) M0 vs M1: peritoneum; (3) M1: other than peritoneum vs M1: peritoneum
NS non significant
M0 M1 M1 p
Other than peritoneum Peritoneum
Age at diagnosis (years) 60.19 (± 12.92) 60.07 (± 14.2) 56.59 (± 12.52) NS
BMI (kg/m2) 25.89 (± 4.9) 25.86 (± 5.11) 22.42 (± 4.97) (2, 3)
Tobacco smoke 7.5 % (168/2230) 4.3 % (9/208) 0 % (0/19) NS
Familial history of breast cancer 36 % (283/787) 33.9 % (21/62) 50 % (1/2) NS
Use of OC 29.7 % (156/525) 24.5 % (12/49) 0 % (0/2) NS
Post-menopausal status 79.6 % (2110/2652) 78.1 % (196/251) 70 % (14/20) NS
First breast surgical treatment
 Breast conserving surgery 62.9 % (1767/2807) 33.7 % (90/267) 54.5 % (12/22) (1, 3)
 Mastectomy 37.1 % (1040/2807) 66.3 % (177/267) 45.5 % (10/22) (1, 3)
Axilla surgical treatment
 CALND 53.8 % (1511/2807) 90.3 % (241/267) 86.4 % (19/22) (1,2)
 SLNB 42.5 % (1194/2807) 5.6 % (15/267) 9.1 % (2/22) (1, 2)
 None 3.6 % (102/2807) 4.1 % (11/267) 4.5 % (1/22) NS
Second breast surgical treatment
 None 77 % (1285/1669) 65.9 % (54/82) 81.8 % (9/11) (1)
 Breast conservative surgery 10.7 % (178/1669) 14.6 % (12/82) 0 % (0/11) NS
 Mastectomy 12.3 % (206/1669) 19.5 % (16/82) 18.2 % (2/11) NS
Other treatments
 Neoadjuvant 5.6 % (158/2807) 15.7 % (42/267) 9.1 % (2/22) (1)
 Adjuvant radiotherapy 58 % (1561/2690) 47.8 % (121/253) 50 % (11/22) (1)
 Adjuvant chemotherapy 39.1 % (1051/2687) 82.9 % (208/251) 86.4 % (19/22) (1, 2)
 Adjuvant hormonal therapy 79.7 % (2140/2684) 64.5 % (162/251) 72.7 % (16/22) (1)
Page 4 of 8Bertozzi et al. SpringerPlus  (2015) 4:688 
Table 2 Tumor characteristics and staging among controls (M0) and women affected by peritoneal carcinomatosis (M1: 
peritoneum) or other site of metastases (M1: other than peritoneum)
Significant differences (p < 0.05) between: (1) M0 vs M1: other than peritoneum; (2) M0 vs M1: peritoneum; (3) M1: other than peritoneum vs M1: peritoneum
NS non significant
Other differences: (1*) p = 0.060; (3*) p = 0.051; (1**) p = 0.058; (3**) p = 0.070
M0 M1 M1 p
Other than peritoneum Peritoneum
Histological type
 Ductal invasive carcinoma 77.4 % (2173/2807) 66.7 % (178/267) 50 % (11/22) (1, 2)
 Lobular invasive carcinoma 12.1 % (340/2807) 16.5 % (44/267) 36.4 % (8/22) (1, 2, 3)
 Ductal and lobular invasive carcinoma 6.7 % (189/2807) 12.7 % (34/267) 9.1 % (2/22) (1)
 Other invasive carcinoma 3.7 % (105/2807) 4.1 % (11/267) 4.5 % (1/22) NS
Molecular Subtype
 Luminal A 32.9 % (923/2807) 13.5 % (36/267) 31.8 % (7/22) (1, 3)
 Luminal B 23.2 % (652/2807) 29.6 % (79/267) 31.8 % (7/22) (1)
 Luminal Her 5.5 % (153/2807) 8.2 % (22/267) 9.1 % (2/22) (1*)
 Her enriched 4 % (111/2807) 8.6 % (23/267) 0 % (0/22) (1)
 Basal-like 7.3 % (205/2807) 16.5 % (44/267) 9.1 % (2/22) (1)
 Non described 27.2 % (763/2807) 23.6 % (63/267) 18.2 % (4/22) NS
Other characteristics of the primary tumor
 ER positives 85.2 % (2284/2680) 71.7 % (180/251) 90.9 % (20/22) (1, 3*)
 PgR positives 73 % (1958/2681) 55.8 % (140/251) 59.1 % (13/22) (1)
 HER2/neu positives 11.8 % (267/2254) 19.4 % (45/232) 9.5 % (2/21) (1)
 Ki-67/Mib-1 >20 33.7 % (671/1994) 61.1 % (113/185) 29.4 % (5/17) (1, 3)
 Comedo-like necrosis 8.7 % (243/2807) 7.9 % (21/267) 0 % (0/22) NS
 Multifocality/multicentricity 20.2 % (567/2807) 22.5 % (60/267) 18.2 % (4/22) NS
 Extensive intraductal component 27.2 % (764/2807) 21.3 % (57/267) 13.6 % (3/22) (1)
 Lymphovascular invasion 15.6 % (439/2807) 26.6 % (71/267) 18.2 % (4/22) (1)
 Peritumoral inflammation 3.3 % (93/2807) 9.4 % (25/267) 0 % (0/22) (1)
Loco-regional lymph nodes characteristics
 Non-axillary loco-regional lymph nodes 1.7 % (48/2807) 1.5 % (4/267) 0 % (0/22) NS
 Isolated tumor cells 2 % (56/2807) 0.4 % (1/267) 0 % (0/22) (1**)
 Micrometastases 4.9 % (138/2807) 4.1 % (11/267) 4.5 % (1/22) NS
 Extracapsular invasion of lymph node metastasis 7.1 % (198/2807) 28.1 % (75/267) 36.4 % (8/22) (1, 2)
 Bunched axillary lymph nodes 2.1 % (58/2807) 18 % (48/267) 31.8 % (7/22) (1, 2)
TNM
 T1 75.4 % (2116/2807) 41.2 % (110/267) 68.2 % (15/22) (1,3)
 T2 20.9 % (586/2807) 37.8 % (101/267) 13.6 % (3/22) (1, 3**)
 T3 1.6 % (44/2807) 10.1 % (27/267) 4.5 % (1/22) (1)
 T4 2.2 % (61/2807) 10.9 % (29/267) 13.6 % (3/22) (1, 2)
 N0 69.9 % (1961/2807) 32.6 % (87/267) 36.4 % (8/22) (1, 2)
 N1 21.2 % (594/2807) 23.2 % (62/267) 13.6 % (3/22) NS
  N2 5.3 % (150/2807) 17.2 % (46/267) 9.1 % (2/22) (1)
 N3 3.6 % (102/2807) 27 % (72/267) 40.9 % (9/22) (1, 2)
Grading
 G1 15.8 % (444/2807) 2.6 % (7/267) 0 % (0/22) (1, 2)
 G2 60.3 % (1693/2807) 49.8 % (133/267) 90.9 % (20/22) (1, 2, 3)
 G3 23.9 % (670/2807) 47.6 % (127/267) 9.1 % (2/22) (1, 3)
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follow up (Fig.  1a). If we consider overall survival from 
the date of metastasis diagnosis, brain and peritoneal sec-
ondaries resulted to have the worst prognosis (Fig. 1b). In 
particular, the lower overall survival of peritoneal carci-
nomatosis becomes statistically significant in comparison 
with all other metastatic site considering the first 2 years 
from its diagnosis (p < 0.05), time after which they align 
with the survival of other metastatic sites. Finally, consid-
ering the Cox proportional hazards multivariate regres-
sion model analysis, after adjusting data for basal-like 
molecular subtype and grading, peritoneal carcinomato-
sis resulted to be an independent risk factor for reduced 
survival in comparison with other metastatic sites (HR 
1.70, 95 % C.I. 1.00–2.90, p < 0.05).
Table 3 Risk factors for  distant metastases (M1) in  multi-
variate logistic regression analysis: (A) considering TNM 
stage I, II, III, and IV at diagnosis; (B) considering only TNM 
stage I, II, and III at diagnosis
OR (C.I. 95 %) p
(A)
 Grading 1.64 (1.25–2.15) <0.05
 Histological type
  Ductal invasive carcinoma Referral 1.000
  Lobular invasive carcinoma 1.80 (1.21–2.65) <0.05
  Ductal and lobular invasive carcinoma 1.68 (1.07–2.64) <0.05
  Other invasive carcinoma 1.23 (0.60–2.51) 0.570
 Molecular subtype
  Luminal A Referral 1.000
  Luminal B 1.86 (1.21–2.87) <0.05
  Luminal Her 2.34 (1.29–4.23) <0.05
  Her enriched 2.20 (1.15–4.22) <0.05
  Basal-like 2.89 (1.69–4.94) <0.05
  Non described 1.87 (1.20–2.93) <0.05
 TNM
  T1 Referral 1.000
  T2 1.53 (1.12–2.11) <0.05
  T3 3.87 (2.16–6.92) <0.05
  T4 2.62 (1.50–4.58) <0.05
  N0 Referral 1.000
  N1 2.00 (1.41–2.85) <0.05
  N2 4.26 (2.78–6.53) <0.05
  N3 8.81 (5.81–13.37) <0.05
(B)
 Grading 1.55 (1.15–2.09) <0.05
 Histological type
  Ductal invasive carcinoma Referral 1.000
  Lobular invasive carcinoma 1.96 (1.29–3) <0.05
  Ductal and lobular invasive carcinoma 1.5 (0.9–2.48) 0.118
  Other invasive carcinoma 0.79 (0.3–2.07) 0.629
 Molecular subtype
  Luminal A Referral 1.000
  Luminal B 2.42 (1.48–3.97) <0.05
  Luminal Her 2.61 (1.33–5.13) <0.05
  Her enriched 2.28 (1.07–4.84) <0.05
  Basal-like 3.66 (2–6.72) <0.05
  Non described 2.26 (1.35–3.78) <0.05
 TNM
  T1 Referral 1.000
  T2 1.55 (1.09–2.19) <0.05
  T3 3.12 (1.62–6.03) <0.05
  T4 2.16 (1.13–4.13) <0.05
  N0 Referral 1.000
  N1 2.23 (1.51–3.28) <0.05
  N2 4.79 (3–7.63) <0.05
  N3 7.95 (4.96–12.73) <0.05
Table 4 Risk factors for  peritoneal carcinomatosis (M1: 
peritoneum) in  multivariate logistic regression analysis: 
(A) considering TNM stage I, II, III, and IV at diagnosis; (B) 
considering only TNM stage I, II, and III at diagnosis
OR (C.I. 95 %) p
(A)
 Grading 1.93 (1.47–2.54) <0.05
 Histological type
  Ductal invasive carcinoma Referral 1.000
  Lobular invasive carcinoma 1.71 (1.13–2.57) <0.05
  Ductal and lobular invasive carcinoma 1.54 (0.95–2.52) 0.083
  Other invasive carcinoma 1 (0.4–2.5) 0.999
 Peritumoral inflammation 1.74 (1–3.01) 0.050
 TNM
  T1 Referral 1.000
  T2 1.56 (1.11–2.21) <0.05
  T3 3.26 (1.69–6.28) <0.05
  T4 2.06 (1.07–3.99) <0.05
  N0 Referral 1.000
  N1 2.23 (1.52–3.27) <0.05
  N2 4.8 (3.03–7.62) <0.05
  N3 7.64 (4.81–2.12) <0.05
(B)
 Histological type
  Ductal invasive carcinoma Referral 1.000
  Lobular invasive carcinoma 3.58 (1.09–11.75) <0.05
  Ductal and lobular invasive carcinoma 2.57 (0.51–12.83) 0.251
  Other invasive carcinoma 3.67 (0.43–31.53) 0.237
 TNM
  T1 Referral 1.000
  T2-3-4 0.31 (0.09–1.13) 0.076
  N0 Referral 1.000
  N1 2.2 (0.52–9.33) 0.287
  N2 6.36 (1.15–35.22) <0.05
  N3 17.74 (4.52–69.63) <0.05
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Discussion
Distant metastasis prevalence among breast cancer 
patients resulted 9.3  % (289/3096), in the 19.7  % of 
metastatic cases metastases were synchronous with 
the primary cancer diagnosis, whereas in the remaining 
80.3  % metastases were metachronous after 83  months 
of median follow up. Peritoneal carcinomatosis had a 
prevalence of 0.7 % (22/3096), and developed later than 
all other sites secondaries. By multivariate analysis, high 
grading, lobular invasive histotype, and advanced TNM 
stage resulted significantly predictive for peritoneal car-
cinomatosis. Overall metastasis rate resulted 5  % at 
10 years, and even 25 % by considering separately stage 
III cancers. Median survival after the diagnosis of metas-
tasis resulted 28 months, and was significantly lower for 
brain and peritoneal secondaries.
The literature did rarely mention peritoneal metastasis 
from breast cancer, and described peritoneal recurrences 
after a variable time interval between 5 and 10 years from 
the diagnosis of primary breast cancer (Eitan et al. 2003; 
Bigorie et  al. 2010; Tserkezoglou et  al. 2006; Garg et  al. 
2013). This late onset might not always be related to a late 
metastasis development rather than to a late metastasis 
detection, which results very difficult in the absence of 
any specific symptom. Moreover, modern imaging tech-
niques resulted scarcely accurate in peritoneal carcino-
matosis diagnosis. In fact, CT scan has an important size 
limit for lesions detection, especially in some critical sites 
like the small bowel walls (Pasqual et  al. 2014; Pasqual 
et al. 2012), while FDG-PET/CT has a high rate of false 
positives due to tissue inflammation following medi-
cal and radiation therapies, as well as a high rate of false 
negatives because of metabolic inactivity of dormant 
neoplastic cells after chemotherapy (Pasqual et al. 2014; 
Pasqual et al. 2012).
In our population, peritoneal metastases prevalence 
resulted even 0.7  % (22/3096), and thus just little lower 
than brain metastasis prevalence. Considering the late 
onset of peritoneal recurrence in our population, their 
prevalence may be the result of an increased survival of 
breast cancer women affected by other sites metastasis 
thanks to the progressive improvement of medical and 
radiological therapies, who consequently gain enough 
time to develop peritoneal metastases. And actually, the 
most cases of peritoneal involvement by breast cancer 
(81.8 %) were associated with metastases in other sites.
Focusing on the risk factors for peritoneal metasta-
sis among patients affected by breast cancer, our data 
highlight a high prevalence of lobular invasive histotype 
among women who develop peritoneal metastasis, but 




















































































Fig. 1 a Cumulative distant metastases appearance during the fol-
low-up and TNM stage at diagnosis, b 2 years overall survival after the 
appearance of distant metastases. The difference between women 
affected by pertitoneal carcinomatosis (M1—peritoneum) and other 
metastases (excluding brain) was statistically significant (p < 0.05) as 
well as the difference between women affected by brain metastases 
and women affected by other metastases (p < 0.05). c Two years 
overall survival after the appearance of peritoneal carcinomatosis 
(M1—peritoneum) in our population and in cases referred by the 
literature to be treated by HIPEC procedure (Cardi et al. 2013; Garofalo 
et al. 2006). We found a significant longer survival in patients treated 
by HIPEC procedure (p < 0.05)
Page 7 of 8Bertozzi et al. SpringerPlus  (2015) 4:688 
the literature is very controversial about a histological 
predisposition. In fact, some Authors described a higher 
prevalence of invasive lobular carcinoma among patients 
with peritoneal secondaries than controls (up to 40  %) 
(Cardi et  al. 2013), and an important predisposition of 
invasive lobular carcinoma to metastasize to any site of 
the digestive tract (Nazareno et al. 2006; Borst and Ingold 
1993). On the other side, some Authors showed a preva-
lence of invasive ductal carcinoma comparable with that 
of their general breast cancer population (77 %) (Tuthill 
et al. 2009; Glass et al. 2007).
Furthermore, some Authors described a higher preva-
lence of peritoneal carcinomatosis among women with 
documented mutations of the BrCa genes, which may 
also be interpreted as a new primary tumor from ovary, 
fallopian tube or peritoneum itself, all cancers which 
BrCa mutated patients are also predisposed to (Hewitt 
et  al. 2006). A retrospective study among women with 
peritoneal metastasis from breast cancer observed a 
prevalence of peritoneal disease from ovarian cancer or 
primary peritoneal malignancy of even 74.7 %, while just 
the remaining 25.3 % of carcinomatosis resulted derived 
from the previous breast cancer (Garg et al. 2013). In our 
population, we found a weak association between famil-
ial history of breast cancer and peritoneal metastasis, but 
data lack about both eventual BrCa mutations and peri-
toneal disease histology, so that we can not completely 
exclude the possibility of a new primary.
For what concerns the prognosis of metastatic breast 
cancer, peritoneal secondaries showed a very poor sur-
vival, as well as brain ones. During the last decades, the 
progress in loco-regional integrated treatments allowed a 
significant improvement in breast metastasis control, or 
even annihilation. We might cite the development of tar-
geted biological drugs against some specific breast can-
cer subtypes, the possibility of using bone cement against 
destructive bone metastasis, the application of interven-
tional radiological techniques against liver secondar-
ies, the minimal invasive and selective surgery against 
lung lesions, and the use of gamma knife against brain 
secondaries.
In this perspective, surgical cytoreduction and HIPEC 
showed encouraging results among selected patients 
treated in specialized centers. Although nowadays this 
procedure results standardized only for peritoneal car-
cinomatosis deriving by cancers of the digestive tract or 
the female genital system, recently some patients with 
peritoneal metastasis from breast cancers successfully 
underwent this treatment (Cardi et  al. 2013; Garofalo 
et al. 2006).
Despite the small number of patients treated with 
cytoreduction and HIPEC, their survival resulted surely 
longer than those who underwent surgical debulking 
without HIPEC and those who were given only systemic 
chemotherapy. In particular, in the literature patients 
who underwent surgical debulking resulted to have sur-
vivals between 10 and 54  months from the diagnosis of 
peritoneal carcinomatosis (Eitan et al. 2003; Bigorie et al. 
2010; Tserkezoglou et  al. 2006; Garg et  al. 2013; Ayhan 
et  al. 2005), and thus comparable with those of other 
metastatic breast cancer women (Altekruse et  al. 2010; 
Jemal et al. 2004), as well as with those affected by stage 
III ovarian cancer (Eitan et  al. 2003; Bigorie et  al. 2010; 
Tserkezoglou et  al. 2006; Garg et  al. 2013; Moore et  al. 
2012). Finally, if we compare patients who underwent 
cytoreduction and HIPEC for breast peritoneal metasta-
sis (data from the literature) (Cardi et al. 2013; Garofalo 
et  al. 2006) with our patients affected by breast cancer 
peritoneal disease who were simply given palliative sys-
temic chemotherapy, overall survival resulted signifi-
cantly longer in the first group (Fig. 1c).
In conclusion, the prognosis of peritoneal metastasis 
from breast cancer resulted very poor. Anyway, we can 
suggest that in at least the 20 % of them, who presented 
with isolated peritoneal breast cancer recurrence, sur-
gical cytoreduction and HIPEC might be feasible and 
effective in improving their overall survival and, most 
important, their quality of life.
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